Mike VanWyngarden, BS
Professional Research Assistant Emeritus
Mike left the lab in December 2018 after working with us for 2 ½ years. During this time, he focused on the development of ex vivo drug sensitivity profiling assay on primary samples which we continue to optimize to measure clinical drug resistance and guide development of new agents for myeloma. This work in currently under review for publication. Mike also conducted multiple in vivo mouse model experiments, including implementation of a technically challenging myeloma patient-derived xenograft model. In addition, Mike generated the firefly luciferase myeloma cell lines that we continue to use in xenograft experiments testing out new drug approaches to this disease. Mike has now joined the Hematology Clinical Trials Unit at our cancer center as a Clinical Research Coordinator towards his ultimate goal of a career in patient care.